Shasqi Announces Expansion of Its Leadership Team
February 23, 2023
Jean Viret, PhD appointed as Chief Financial Officer to drive financial strategy for Shasqi platform expansion
SAN FRANCISCO, CA., February 23, 2023 — Shasqi, Inc. (“Shasqi”), a clinical stage biotechnology company whose goal is to transform cancer outcomes through the pairing of click chemistry with cancer therapeutics, today announced the appointment of industry veteran Jean-Frédéric Viret, PhD as Chief Financial Officer.
“We are thrilled to welcome Jean to our leadership team”, said Dr. José Mejía Oneto, Founder and CEO of Shasqi. “Jean’s industry experience and knowledge of leading financial strategies will prove crucial in our planned expansion of our CAPAC™ platform, and the evolution of Shasqi into our next phase of growth.”
Jean joins Shasqi from Blade Therapeutics, Inc., where, as CFO, he led their finance, accounting, and investor relations, including leading the filing of a Form S-4 as part of a SPAC merger. Prior to Blade, Jean held a variety of CFO positions in the biotech industry including at Coherus Biosciences, Inc., where he led its initial public offering and multiple equity and debt financings, diaDexus, Inc. and XDx, Inc. (now CareDx, Inc.). Jean has a PhD in Plant Molecular Biology from the University of Strasbourg and an MBA from Cornell University.
“I was inspired to join Shasqi when I learned about their ability to activate well-characterized anti-cancer agents only around the tumor and tumor micro-environment,” said Dr. Jean Viret. “Click chemistry and Shasqi’s unique CAPAC platform hold immense potential to transform the way we treat cancer patients and improve both the safety and efficacy of these highly toxic drugs. I am excited to contribute to advancing Shasqi’s mission for the benefit of cancer patients.”
Shasqi is leveraging the power of Nobel-prize winning technology, click chemistry, to activate cancer treatments at the site of the tumor. Its Click Activated Protodrugs Against cancer (CAPAC) platform has the potential to expand the therapeutic index of cancer drugs, while enhancing safety and toxicity.
Shasqi is currently the only company using click chemistry in humans and is rapidly advancing its pipeline with a Phase 2 study in progress for their lead product.